Safety, Immunogenicity and efficacy of Autoclaved leishmania major vaccine (ALM) in an endemic area of L.donovani infection in eastern Sudan. TDR/WHO. [Concluded]
Safety and immunogenicity of ALUM/ALM vaccine in Healthy Sudanese volunteers. TDR/WHO. [Concluded]
Immunochemotherapy for patients with persistent post kala-azar dermal leishmaniasis (PKDL) using Alum-precipitated ALM+BCG vaccine and sodium stibogluconate: a hospital-based approach. TDR/WHO. [Concluded]
Immune profile and clinical presentations of patients with tuberculous lymphadenitis in the Sudan. University of Khartoum/Sudan. [Concluded]
Latent M.tuberculosis infection: prevalence & Risk Factors in Central & Eastern Sudan. University of Khartoum/Sudan. [On Going]
Anaemia of chronic malaria: the role of depressed erythropoietin response. [Concluded]
Congenital Malaria: a neonatal prospectus. University of Khartoum/Sudan. [Concluded]
Sickle cell anaemia: a card/registry system for the control of HbS in nomadic tribes in western Sudan. University of Khartoum/Sudan. [Concluded]
Sickle haemoglobin screening: Cellulose acetate versus ID technique. University of Khartoum/Sudan. [Concluded]
AID to displaced people in Sudan: magnitude and efficiency. University of Khartoum/Sudan. [Concluded]
Sickle Disease Prevention: A card-registry system for prevention of Sickle cell disease among the Meissairya Tribes of Western Sudan. [Awaiting funding]
Safety & Efficacy of SSG/Paromomycin combination in the treatment of Primary Sudanese Visceral Leishmaniasis. (DNDi_Geneva/LEAP 0104 A;DNDi_Geneva /LEAP 0104 B). Leishmaniasis East Africa Platform. [Concluded]
Safety and efficacy of Single Dose Ambisome for the treatment of Visceral Leishmaniasis in East Africa: a multicentre, randomized trial.. (DNDi_Geneva/LEAP 0106). [Concluded]
LeishF2/SSG Immunochemotherapy for the treatment of patients with persistent PKDL. IDRI; Seattle, USA/Institute of Endemic Diseases, University of Khartoum, Sudan. (Concluded 2011).
Safety & Efficacy of Miltefosine/Ambisome Combination for the treatment of visceral leishmaniasis in East Africa: a multicentre, randomized trial. (DNDi_Geneva /LEAP 0208). [On Going]
In silico prediction of T-cells epitopes of L.donovani as candidate subunit vaccines for visceral leishmaniasis. (/Institute of Endemic Diseases, University of Khartoum, Sudan). [On Going]
Immunochemotherapy for patients with persistent PKDL using Alumprecipitated ALM+BCG vaccine and sodium stibogluconate: a field approach.TDR/WHO/Institute of Endemic Diseases, University of Khartoum, Sudan. (Awaiting funding).
